Compare Abeona Therapeutics Inc (ABEO) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while First Trust NASDAQ Cybersecurity ETF trades at $91.45. Which is the better fit depends on your goals.
| ABEO | CIBR | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $94.32 |
52-Week Low | $4.17 | $60.74 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CIBR (First Trust NASDAQ Cybersecurity ETF) trades at $92.21, up 1.7% with strong bullish momentum. Technical indicators show moving averages in bullish alignment while oscillators signal neutral conditions. The ETF has significantly outperformed the S&P 500, gaining approximately 22% year-to-date through June 2026 versus 8% for the broader market. Recent news highlights growing cybersecurity spending exceeding $300 billion globally, with CIBR positioned as a clean play on AI-driven security demand.
The cybersecurity sector benefits from structural growth drivers including AI-powered threats and mandatory corporate spending. CIBR offers diversified exposure to 30+ cybersecurity companies with reasonable valuation at 24x P/E. Key risks include concentrated tech exposure and market volatility, but institutional buying and positive analyst sentiment support the bullish outlook for this thematic ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
